<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 21 May 2021 17:24:27 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>礼来双激动剂降糖药Tirzepatide第5项III期试验成功！降糖减重优于甘精胰岛素</title><link>https://mp.weixin.qq.com/s/FGSncU1rbA1ZNPu0VGVH3g</link><description></description><content:encoded><![CDATA[礼来双激动剂降糖药Tirzepatide第5项III期试验成功！降糖减重优于甘精胰岛素]]></content:encoded><pubDate>Fri, 21 May 2021 16:35:00 +0800</pubDate></item><item><title>ORR：95%，传奇生物CAR-T疗法临床研究再传捷报！上市申请已获EMA受理</title><link>https://mp.weixin.qq.com/s/JCl3NlGYNcdrKOGf596IbA</link><description></description><content:encoded><![CDATA[ORR：95%，传奇生物CAR-T疗法临床研究再传捷报！上市申请已获EMA受理]]></content:encoded><pubDate>Fri, 21 May 2021 16:35:00 +0800</pubDate></item><item><title>PFS翻倍！LAG-3/PD-1组合疗法首个III期数据公布</title><link>https://mp.weixin.qq.com/s/kWDilHUfrzTA5KmBYqOiPw</link><description></description><content:encoded><![CDATA[PFS翻倍！LAG-3/PD-1组合疗法首个III期数据公布]]></content:encoded><pubDate>Fri, 21 May 2021 16:35:00 +0800</pubDate></item><item><title>诺华 first in class SHP2抑制剂首个人体临床数据公布</title><link>https://mp.weixin.qq.com/s/WR410oz6SnuZ_TM6rw_JmA</link><description></description><content:encoded><![CDATA[诺华 first in class SHP2抑制剂首个人体临床数据公布]]></content:encoded><pubDate>Fri, 21 May 2021 16:35:00 +0800</pubDate></item><item><title>ASCO 2021 | 科伦药业HER2-ADC 临床数据抢先看</title><link>https://mp.weixin.qq.com/s/00mZYFv8ExSjiZjDvzg7Zw</link><description></description><content:encoded><![CDATA[ASCO 2021 | 科伦药业HER2-ADC 临床数据抢先看]]></content:encoded><pubDate>Fri, 21 May 2021 16:35:00 +0800</pubDate></item><item><title>拜耳“不限癌种”疗法在华申报上市，治疗NTRK融合肿瘤</title><link>https://mp.weixin.qq.com/s/x_lkahma2-S5favgKwFzEw</link><description></description><content:encoded><![CDATA[拜耳“不限癌种”疗法在华申报上市，治疗NTRK融合肿瘤]]></content:encoded><pubDate>Thu, 20 May 2021 18:23:41 +0800</pubDate></item><item><title>ASCO2021中国新药临床数据汇总：豪森、亚盛、康宁杰瑞、君实......</title><link>https://mp.weixin.qq.com/s/Wb3cq3dHJGTnYZ6YYFOZ6g</link><description></description><content:encoded><![CDATA[ASCO2021中国新药临床数据汇总：豪森、亚盛、康宁杰瑞、君实......]]></content:encoded><pubDate>Thu, 20 May 2021 18:23:41 +0800</pubDate></item><item><title>ASCO2021摘要精选50篇</title><link>https://mp.weixin.qq.com/s/cUnIW9XRwHK6hxSmlIN8kg</link><description></description><content:encoded><![CDATA[ASCO2021摘要精选50篇]]></content:encoded><pubDate>Thu, 20 May 2021 18:23:41 +0800</pubDate></item><item><title>CheckMate -227四年随访数据公布！欧狄沃联合伊匹木单抗为NSCLC患者（PD-L1 ≥1%）带来持久且长期生存获益</title><link>https://mp.weixin.qq.com/s/G9ucHHw3ZV9aIYc4_veucQ</link><description></description><content:encoded><![CDATA[CheckMate -227四年随访数据公布！欧狄沃联合伊匹木单抗为NSCLC患者（PD-L1 ≥1%）带来持久且长期生存获益]]></content:encoded><pubDate>Thu, 20 May 2021 18:23:41 +0800</pubDate></item><item><title>植物源COVID-19疫苗II期结果积极，已获FDA快速通道资格</title><link>https://mp.weixin.qq.com/s/MqlZZboxAluaJkAYu16D9Q</link><description></description><content:encoded><![CDATA[植物源COVID-19疫苗II期结果积极，已获FDA快速通道资格]]></content:encoded><pubDate>Wed, 19 May 2021 18:15:42 +0800</pubDate></item><item><title>FDA批准的首款EZH2抑制剂在华申报临床</title><link>https://mp.weixin.qq.com/s/Wp_JW2jOf6w0uqPYdrRsdQ</link><description></description><content:encoded><![CDATA[FDA批准的首款EZH2抑制剂在华申报临床]]></content:encoded><pubDate>Wed, 19 May 2021 18:15:42 +0800</pubDate></item><item><title>传奇生物一季报发布：亏损8千万美金，递交多项上市申请</title><link>https://mp.weixin.qq.com/s/clkERcrvD8jNr1f0O0wD1w</link><description></description><content:encoded><![CDATA[传奇生物一季报发布：亏损8千万美金，递交多项上市申请]]></content:encoded><pubDate>Wed, 19 May 2021 18:15:42 +0800</pubDate></item><item><title>开拓药业普克鲁胺获FDA批准开展治疗住院新冠患者III期临床研究</title><link>https://mp.weixin.qq.com/s/zz0nNeXUrgllDdQisDiHOg</link><description></description><content:encoded><![CDATA[开拓药业普克鲁胺获FDA批准开展治疗住院新冠患者III期临床研究]]></content:encoded><pubDate>Wed, 19 May 2021 18:15:42 +0800</pubDate></item><item><title>罗氏全球首个加速器在上海启动，引领中国本土医疗行业创新</title><link>https://mp.weixin.qq.com/s/0-rSS9tFtOPGcQ_nNd_l2A</link><description></description><content:encoded><![CDATA[罗氏全球首个加速器在上海启动，引领中国本土医疗行业创新]]></content:encoded><pubDate>Tue, 18 May 2021 18:38:55 +0800</pubDate></item><item><title>信达生物PD1单抗美国上市申请获受理</title><link>https://mp.weixin.qq.com/s/4ADsux_IJBMm_YhE-q4f2Q</link><description></description><content:encoded><![CDATA[信达生物PD1单抗美国上市申请获受理]]></content:encoded><pubDate>Tue, 18 May 2021 18:38:55 +0800</pubDate></item><item><title>有望成为首个上市的白癜风治疗药物，芦可替尼乳膏III期研究成功</title><link>https://mp.weixin.qq.com/s/XkcDEnWX19kHZHJ1VFdzEQ</link><description></description><content:encoded><![CDATA[有望成为首个上市的白癜风治疗药物，芦可替尼乳膏III期研究成功]]></content:encoded><pubDate>Tue, 18 May 2021 18:38:55 +0800</pubDate></item><item><title>新一代HER2-ADC获CDE拟突破性疗法</title><link>https://mp.weixin.qq.com/s/0xv_A_c3hKxoprlKPRHruQ</link><description></description><content:encoded><![CDATA[新一代HER2-ADC获CDE拟突破性疗法]]></content:encoded><pubDate>Tue, 18 May 2021 18:38:55 +0800</pubDate></item><item><title>康方生物CD47单抗骨髓增生异常综合症I/II期研究申请获许可</title><link>https://mp.weixin.qq.com/s/7UHVxBGTriRvz1tVEjzBGw</link><description></description><content:encoded><![CDATA[康方生物CD47单抗骨髓增生异常综合症I/II期研究申请获许可]]></content:encoded><pubDate>Tue, 18 May 2021 18:38:55 +0800</pubDate></item><item><title>诺诚健华自研新型TYK2抑制剂ICP-332获批临床</title><link>https://mp.weixin.qq.com/s/XkAZGQm7ydaqS77SoH-BTQ</link><description></description><content:encoded><![CDATA[诺诚健华自研新型TYK2抑制剂ICP-332获批临床]]></content:encoded><pubDate>Tue, 18 May 2021 18:38:55 +0800</pubDate></item><item><title>克服BTK耐药，默沙东BTK-C481S抑制剂申报临床</title><link>https://mp.weixin.qq.com/s/9o0DAnZYJeIkeHD5zwAlag</link><description></description><content:encoded><![CDATA[克服BTK耐药，默沙东BTK-C481S抑制剂申报临床]]></content:encoded><pubDate>Tue, 18 May 2021 18:38:55 +0800</pubDate></item></channel></rss>